Psychological factors at early stage of treatment as predictors of receiving chemotherapy at the end of life

Daisuke Fujisawa, Jennifer S. Temel, Lara Traeger, Joseph A. Greer, Inga T. Lennes, Masaru Mimura, William F. Pirl

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Introduction: Administration of chemotherapy in the last 14 days of life is a widely recognized indicator of poor end-of-life (EOL) care. The current study aimed to investigate predictors of this outcome, focusing on patients' self-reported psychological symptoms. Methods and Materials: This is a secondary analysis of a randomized controlled trial that examined the efficacy of early palliative care integrated with standard oncology practice in patients with metastatic non-small cell lung cancer (NSCLC). We analyzed associations between receipt of chemotherapy within 14 days of death and demographic, clinical, and quality-of-life variables in the 125 patients who received chemotherapy in the course of their illness and died during the 50-month follow-up. Results: Twenty-five patients (20%) received chemotherapy within the last 14 days of their life. Among demographic and clinical variables, only route of chemotherapy was significantly associated with receipt of chemotherapy within 14 days of death (oral 34.1% vs. intravenous (IV) 12.3%, p<0.05). In the subsample of participants who received IV chemotherapy as their last regimen, greater anxiety and depression and lower quality of life in emotional, social, and existential domains were associated with greater likelihood of receiving chemotherapy at the EOL. These associations were not observed in patients who received oral chemotherapy as their last regimen. Conclusion: Anxiety, depression, and worse psychological quality of life at early stage of treatment may be associated with the receipt of IV chemotherapy at the EOL.

Original languageEnglish
JournalPsycho-Oncology
DOIs
Publication statusAccepted/In press - 2015

Fingerprint

Psychology
Drug Therapy
Therapeutics
Quality of Life
Anxiety
Demography
Depression
Terminal Care
Palliative Care
Non-Small Cell Lung Carcinoma
Randomized Controlled Trials

ASJC Scopus subject areas

  • Oncology
  • Psychiatry and Mental health
  • Experimental and Cognitive Psychology

Cite this

Psychological factors at early stage of treatment as predictors of receiving chemotherapy at the end of life. / Fujisawa, Daisuke; Temel, Jennifer S.; Traeger, Lara; Greer, Joseph A.; Lennes, Inga T.; Mimura, Masaru; Pirl, William F.

In: Psycho-Oncology, 2015.

Research output: Contribution to journalArticle

Fujisawa, Daisuke ; Temel, Jennifer S. ; Traeger, Lara ; Greer, Joseph A. ; Lennes, Inga T. ; Mimura, Masaru ; Pirl, William F. / Psychological factors at early stage of treatment as predictors of receiving chemotherapy at the end of life. In: Psycho-Oncology. 2015.
@article{2aee33f2fa1c45fdb4a7c9709be2bc10,
title = "Psychological factors at early stage of treatment as predictors of receiving chemotherapy at the end of life",
abstract = "Introduction: Administration of chemotherapy in the last 14 days of life is a widely recognized indicator of poor end-of-life (EOL) care. The current study aimed to investigate predictors of this outcome, focusing on patients' self-reported psychological symptoms. Methods and Materials: This is a secondary analysis of a randomized controlled trial that examined the efficacy of early palliative care integrated with standard oncology practice in patients with metastatic non-small cell lung cancer (NSCLC). We analyzed associations between receipt of chemotherapy within 14 days of death and demographic, clinical, and quality-of-life variables in the 125 patients who received chemotherapy in the course of their illness and died during the 50-month follow-up. Results: Twenty-five patients (20{\%}) received chemotherapy within the last 14 days of their life. Among demographic and clinical variables, only route of chemotherapy was significantly associated with receipt of chemotherapy within 14 days of death (oral 34.1{\%} vs. intravenous (IV) 12.3{\%}, p<0.05). In the subsample of participants who received IV chemotherapy as their last regimen, greater anxiety and depression and lower quality of life in emotional, social, and existential domains were associated with greater likelihood of receiving chemotherapy at the EOL. These associations were not observed in patients who received oral chemotherapy as their last regimen. Conclusion: Anxiety, depression, and worse psychological quality of life at early stage of treatment may be associated with the receipt of IV chemotherapy at the EOL.",
author = "Daisuke Fujisawa and Temel, {Jennifer S.} and Lara Traeger and Greer, {Joseph A.} and Lennes, {Inga T.} and Masaru Mimura and Pirl, {William F.}",
year = "2015",
doi = "10.1002/pon.3840",
language = "English",
journal = "Psycho-Oncology",
issn = "1057-9249",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Psychological factors at early stage of treatment as predictors of receiving chemotherapy at the end of life

AU - Fujisawa, Daisuke

AU - Temel, Jennifer S.

AU - Traeger, Lara

AU - Greer, Joseph A.

AU - Lennes, Inga T.

AU - Mimura, Masaru

AU - Pirl, William F.

PY - 2015

Y1 - 2015

N2 - Introduction: Administration of chemotherapy in the last 14 days of life is a widely recognized indicator of poor end-of-life (EOL) care. The current study aimed to investigate predictors of this outcome, focusing on patients' self-reported psychological symptoms. Methods and Materials: This is a secondary analysis of a randomized controlled trial that examined the efficacy of early palliative care integrated with standard oncology practice in patients with metastatic non-small cell lung cancer (NSCLC). We analyzed associations between receipt of chemotherapy within 14 days of death and demographic, clinical, and quality-of-life variables in the 125 patients who received chemotherapy in the course of their illness and died during the 50-month follow-up. Results: Twenty-five patients (20%) received chemotherapy within the last 14 days of their life. Among demographic and clinical variables, only route of chemotherapy was significantly associated with receipt of chemotherapy within 14 days of death (oral 34.1% vs. intravenous (IV) 12.3%, p<0.05). In the subsample of participants who received IV chemotherapy as their last regimen, greater anxiety and depression and lower quality of life in emotional, social, and existential domains were associated with greater likelihood of receiving chemotherapy at the EOL. These associations were not observed in patients who received oral chemotherapy as their last regimen. Conclusion: Anxiety, depression, and worse psychological quality of life at early stage of treatment may be associated with the receipt of IV chemotherapy at the EOL.

AB - Introduction: Administration of chemotherapy in the last 14 days of life is a widely recognized indicator of poor end-of-life (EOL) care. The current study aimed to investigate predictors of this outcome, focusing on patients' self-reported psychological symptoms. Methods and Materials: This is a secondary analysis of a randomized controlled trial that examined the efficacy of early palliative care integrated with standard oncology practice in patients with metastatic non-small cell lung cancer (NSCLC). We analyzed associations between receipt of chemotherapy within 14 days of death and demographic, clinical, and quality-of-life variables in the 125 patients who received chemotherapy in the course of their illness and died during the 50-month follow-up. Results: Twenty-five patients (20%) received chemotherapy within the last 14 days of their life. Among demographic and clinical variables, only route of chemotherapy was significantly associated with receipt of chemotherapy within 14 days of death (oral 34.1% vs. intravenous (IV) 12.3%, p<0.05). In the subsample of participants who received IV chemotherapy as their last regimen, greater anxiety and depression and lower quality of life in emotional, social, and existential domains were associated with greater likelihood of receiving chemotherapy at the EOL. These associations were not observed in patients who received oral chemotherapy as their last regimen. Conclusion: Anxiety, depression, and worse psychological quality of life at early stage of treatment may be associated with the receipt of IV chemotherapy at the EOL.

UR - http://www.scopus.com/inward/record.url?scp=84929223161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929223161&partnerID=8YFLogxK

U2 - 10.1002/pon.3840

DO - 10.1002/pon.3840

M3 - Article

C2 - 25959002

AN - SCOPUS:84955705604

JO - Psycho-Oncology

JF - Psycho-Oncology

SN - 1057-9249

ER -